Porokeratosis Treatment Market Size, Share, and COVID-19 Impact Analysis By Therapy (Topical, Systemic and Physical {Cryotherapy, Laser Therapy, and Others}), By End User (Hospitals & Clinics, Clinical Laboratories, and Others), and Regional Forecast 2025-2032

Porokeratosis is a rare skin disorder in which abnormal keratinization occurs. It typically appears as a small patch with a raised edge. Porokeratosis is divided into six main subtypes that vary in size, color, and anatomic location. Porokeratosis may develop due to various factors such as UV radiation exposure, random abnormal genetics, drug-related immunosuppression, etc., and is considered a precancerous lesion that can undergo malignant transformation. According to an article published by the National Institutes of Health (NIH) in 2022, the study reported that the porokeratosis condition might progress to nonmelanoma skin cancer in 6.9%-30.0% of cases.

Growing cases of porokeratosis due to various factors have led to an intense need for innovative therapies in the market. Stronger adoption of advanced technologies for cosmetic purposes coupled with suitable reimbursement policies is driving market growth. Also, increasing research and development activities to introduce advanced porokeratosis treatments are expected to generate excellent opportunities for the market.

However, the high cost of therapies and flawed healthcare system, especially in emerging nations, may restrain the market growth.

Impact of COVID-19 on the Porokeratosis Treatment Market

The COVID-19 pandemic had negatively impacted the global market. Due to the COVID-19 pandemic, skin cancer services and aesthetic procedures were halted across the globe.  COVID-19 caused disruptions in patient visits due to the lockdown and the risk of infection among patients. For instance, according to an article published by the National Institutes of Health (NIH) in 2021, COVID-19 profoundly impacted the routine management of skin cancer services. The surgical and therapeutic services for skin cancer were delayed during the COVID-19 pandemic.

Similarly, the COVID-19 pandemic disrupted business activities, including customers and employees of key players during the period. Thus, this resulted in a decline in the annual revenue of the prominent market players. For instance, major players, such as Beiersdorf, have witnessed a drop of 8.2% in 2020 compared to 2019. Also, the company witnessed a recovery of 8.6% in 2021 compared to 2020.

However, in 2021, the market recovered to its pre-pandemic growth regarding patient visits and company sales. The market is anticipated to grow at a pre-pandemic growth rate during the forecast period.

Key Insights

• Prevalence of Porokeratosis, By Key Countries/ Regions, 2022.
• Key Industry Developments.
• Technological Advancements in Porokeratosis Treatment.
• Impact of COVID-19 on the Global Disposable EEG Electrode Market.

Analysis by Therapy:

Based on the therapy, the global porokeratosis treatment market is segmented into topical, systemic, and physical. Physical therapy is sub-segmented cryotherapy, laser therapy, and others. The physical is expected to hold the lion’s share globally. The surge in the usage of physical therapies for therapeutic and aesthetic applications is contributing to the market’s growth.

Also, laser therapies are commonly used on patients with various types of porokeratosis, and the outcomes were positive. According to an article published by STATPEARLS in 2022, laser therapies can be used for disseminated superficial actinic porokeratosis. It was shown that laser therapies could be used to decrease the hyperpigmentation and obliteration of the cornoid lamella. Such factors fuel the market growth.

Regional Analysis:

To gain extensive insights into the market, Download for Customization

In terms of regions, North America accounted for a significant global market share. The dominant share is attributed to robust initiatives by key players to introduce advanced products. Also, the increasing prevalence of skin disorders and vital research initiatives propel regional growth. According to an undergoing study published in clinicaltrails.gov, the Medical University of South Carolina sponsored the study based on disseminated superficial actinic porokeratosis. The study aims to analyze the effects of topical lovastatin/cholesterol vs topical lovastatin alone in patients with DSAP. Such a scenario fuels regional growth in the global market.

Key Players Covered

The report will include the profiles of key players such as Coherent, Inc., Alma Lasers, IRIDEX Corporation, Beiersdorf, Bioventus LLC., Glenmark Pharmaceuticals, Cutera, Lumenis Be Ltd., and others.

Segmentation

Key Industry Developments

• January 2022: Pfizer Inc. received the U.S. Food and Drug Administration (FDA) approval for the CIBINQO (abrocitinib). It is an oral, once-daily Janus kinase 1 (JAK1) inhibitor for treating adults with refractory, moderate-to-severe atopic dermatitis (AD).
• July 2021: Alma Lasers received FDA 510(k) clearance for the Alma Hybrid laser. This laser platform is the first to include an ablative 10,600 nm (CO2) laser and a nonablative 1570 nm laser for skin resurfacing.
• February 2021: Beiersdorf launched its first medical product Eucerin ACTINIC CONTROL SPF100. Due to the influence of the sun’s rays, Actinic keratosis can occur, and it is the world’s most common precursor to nonmelanoma skin cancer.